Overview

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's disease
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
N 0437
Ropinirole
Rotigotine